Patient characteristics
| Characteristics | All patients (N=317) | Patients who mapped bilaterally (N = 194) | Patients who did not map bilaterally (n = 123) | P value |
| Age at diagnosis, years | 0.02 | |||
| Median (min, max) | 62 (27, 87) | 61 (27, 87) | 64 (27, 85) | |
| Race, n (%) | 0.21 | |||
| White/Caucasian | 235 (74) | 147 (76) | 88 (72) | |
| Black/African American | 51 (16) | 27 (14) | 24 (20) | |
| Asian or Asian American | 3 (1) | 3 (2) | 0 (0) | |
| Native American/American Indian | 2 (1) | 0 (0) | 2 (2) | |
| Other | 4 (1) | 3 (2) | 1 (1) | |
| Unknown | 22 (7) | 14 (7) | 8 (7) | |
| Ethnicity, n (%) | 0.53 | |||
| Non-Hispanic | 297 (94) | 181 (93) | 116 (94) | |
| Hispanic | 9 (3) | 7 (4) | 2 (2) | |
| Unknown | 11 (3) | 6 (3) | 5 (4) | |
| BMI, kg/m2 | 0.06 | |||
| Mean (min,max) | 35 (18,72) | 34 (18,72) | 36 (21,62) | |
| Final pathologic stage, no (%) | 0.59* | |||
| IA | 221 (70) | 131 (68) | 90 (73) | |
| IB | 44 (14) | 28 (14) | 16 (13) | |
| II | 12 (4) | 9 (5) | 3 (2) | |
| IIIA | 9 (3) | 7 (4) | 2 (2) | |
| IIIB | 1 (0) | 0 (0) | 1 (0) | |
| IIIC1 | 24 (8) | 16 (8) | 8 (7) | |
| IIIC2 | 5 (2) | 2 (1) | 3 (2) | |
| IVA | 0 (0) | 0 (0) | 0 (0) | |
| IVB | 1 (0) | 1 (1) | 0 (0) | |
| Histology, n (%) | 0.62 | |||
| Endometrioid adenocarcinoma | 262 (83) | 161 (83) | 101 (82) | |
| Serous | 25 (8) | 12 (6) | 13 (11) | |
| Clear cell | 2 (1) | 1 (1) | 1 (1) | |
| Mixed | 14 (4) | 10 (5) | 4 (3) | |
| Carcinosarcoma | 13 (4) | 9 (5) | 4 (3) | |
| Mucinous | 1 (0) | 1 (1) | 0 (0) | |
| Grade, n (%) | 0.43 | |||
| 1 | 158 (50) | 99 (51) | 59 (48) | |
| 2 | 73 (23) | 40 (21) | 33 (27) | |
| 3 | 86 (27) | 55 (28) | 31 (25) | |
| Myometrial invasion, n (%) | 0.71 | |||
| < 50% | 241 (76) | 146 (75) | 95 (77) | |
| ≥ 50% | 72 (23) | 46 (24) | 26 (21) | |
| Missing | 4 (1) | 2 (1) | 2 (2) | |
| Lymphovascular space invasion, n (%) | 0.03 | |||
| No | 239 (75) | 139 (72) | 100 (81) | |
| Yes | 74 (23) | 54 (28) | 20 (16) | |
| Could not determine | 4 (1) | 1 (1) | 3 (2) | |
| Lower uterine segment involvement, n (%) | 0.61 | |||
| No | 223 (70) | 139 (72) | 84 (68) | |
| Yes | 94 (30) | 55 (28) | 39 (32) | |
| Cervical involvement, n (%) | 0.93 | |||
| No | 292 (92) | 178 (92) | 114 (92) | |
| Yes | 25 (8) | 16 (8) | 9 (8) | |
| Tumor size, cm | 0.33 | |||
| Mean (min,max) | 3.3 (0,11.7) | 3.2 (0,10.0) | 3.4 (0,11.7) | |
| Subgroup of patients with stage I endometrioid endometrial cancer |
All patients
(N=231) | Patients who mapped bilaterally (N = 140) | Patients who did not map bilaterally (N = 91) | |
| Risk as defined by GOG 99 risk factors | 1 | |||
| Low–intermediate risk | 193 | 117 | 76 | |
| High–intermediate risk | 38 | 23 | 15 | |
*p Value computed by comparing all patients with stage I, II, III, or IV disease.
BMI, body mass index; GOG, Gynecologic Oncology Group.